Targeting of GRPR by means of peptide radionuclide-carriers has been regarded as a promising approach in the treatment of prostate cancer (Abouzayed et al. 2020; Dumont et al. 2013; Kurth et al. 2020; Mitran et al. 2019). This evidence concerns the gene GRPR and Familial prostate cancer.